“…Between January 2010 and December 2018, 246 patients (155 female and 91 male) were treated with Xgeva ® for bone metastases (120 mg Denosumab every 4 weeks) or giant cell bone tumor (120 mg Denosumab every 4 weeks with 2 additional doses of 120 mg in the first month of treatment). The median follow-up time was 16 months (IQR [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]). At the last follow-up, 38 patients (24 female and 14 male) developed MRONJ.…”